-
公开(公告)号:US06204293B1
公开(公告)日:2001-03-20
申请号:US09073807
申请日:1998-05-07
申请人: Said M. Sebti , Andrew D. Hamilton , David J. Augeri , Kenneth J. Barr , Stephen A. Fakhoury , David A. Janowick , Douglas M. Kalvin , Stephen J. O'Connor , Saul H. Rosenberg , Wang Shen , Rolf E. Swenson , Bryan K. Sorensen , Gerard M. Sullivan , Andrew S. Tasker , James T. Wasicak , Lissa T. J. Nelson , Kenneth J. Henry , Le Wang , Gang Liu , Indrani W. Gunawardana
发明人: Said M. Sebti , Andrew D. Hamilton , David J. Augeri , Kenneth J. Barr , Stephen A. Fakhoury , David A. Janowick , Douglas M. Kalvin , Stephen J. O'Connor , Saul H. Rosenberg , Wang Shen , Rolf E. Swenson , Bryan K. Sorensen , Gerard M. Sullivan , Andrew S. Tasker , James T. Wasicak , Lissa T. J. Nelson , Kenneth J. Henry , Le Wang , Gang Liu , Indrani W. Gunawardana
IPC分类号: C07C26302
CPC分类号: C07C237/36 , C07B2200/07 , C07C239/20 , C07C271/22 , C07C317/50 , C07C323/59 , C07C323/60 , C07C327/42 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2602/08 , C07C2603/18 , C07C2603/24 , C07C2603/74 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/26 , C07D207/267 , C07D209/48 , C07D211/14 , C07D211/42 , C07D211/52 , C07D211/58 , C07D213/30 , C07D213/32 , C07D213/34 , C07D213/36 , C07D213/38 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/70 , C07D213/71 , C07D213/74 , C07D213/75 , C07D213/76 , C07D213/82 , C07D213/89 , C07D231/12 , C07D233/56 , C07D233/64 , C07D233/90 , C07D235/06 , C07D237/14 , C07D239/26 , C07D239/42 , C07D241/04 , C07D241/12 , C07D241/18 , C07D249/08 , C07D253/06 , C07D257/04 , C07D261/02 , C07D263/22 , C07D263/32 , C07D265/30 , C07D277/30 , C07D277/36 , C07D277/48 , C07D277/50 , C07D277/587 , C07D279/12 , C07D295/084 , C07D295/13 , C07D295/155 , C07D295/185 , C07D307/54 , C07D307/81 , C07D317/30 , C07D317/60 , C07D333/18 , C07D333/20 , C07D333/24 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/08 , C07F9/5333
摘要: Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5 —, (f) —L4—N(R5)—C(W)—L7—L5 —, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
摘要翻译: 具有式的化合物或其药学上可接受的盐,其中R 1是(a)氢,(b)低级烷基,(c)烯基,(d)烷氧基,(e)硫代烷氧基,(f)卤素,(g)卤代烷基,(h) 芳基-L2-和(i)杂环-L2-; R2选自(b)-C(O)NH-CH(R14)-C(O)OR15,(d)-C(O)NH-CH(R14)-C(O)NHSO2R16,(e) C(O)NH-CH(R 14) - 四唑基,(f)-C(O)NH-杂环基和(g)-C(O)NH-CH(R 14)-C(O)NR 17 R 18; R3是杂环,芳基,取代或未取代的环烷基; R4是氢,低级烷基,卤代烷基,卤素,芳基,芳基烷基,杂环或(杂环)烷基; (a)-L4-N(R5)-L5-,(b)-L4-O-L5-,(c)-L4-S(O)n-L5-(d) - L4-L6-C(W)-N(R5)-L5-,(e)-L4-L6-S(O)mN(R5)-L5 - ,(f)-L4-N(R5)-C W)-L7-L5 - ,(g)-L4-N(R5)-S(O)p-L7-L5-,(h)任选取代的亚烷基,(i)任选取代的亚烯基,和(j) 亚炔基是蛋白质异戊二烯转移酶的抑制剂。 还公开了蛋白质异戊二烯转移酶抑制组合物和抑制蛋白质异戊二烯转移酶的方法。